Clinical Trials Logo

Clinical Trial Summary

The purpose of this study is to evaluate the effect of rizatriptan, alone or combined with caffeine for treating acute attacks of migraine.

Each subject will have 3 months to treat 3 acute migraine headache attacks. Each subject will be dispensed one box containing 3 packets of study medication labeled for Headache #1, Headache #2, or Headache #3. Each packet wil contain either Maxalt 10mg MLT or a Maxalt placebo (sugar pill), and a capsule containing either caffeine 75mg or a capsule containing placebo (sugar).

One headache will be treated with a combination of Maxalt 10mg MLT and caffeine.

Another headache will be treated with a combination of Maxalt 10mg MLT and a capsule containing placebo.

A third headache will be treated with just placebo.

Neither the subject, the study coordinator, or your study doctor will know in which order you will receive the three different treatments. This information is available in case of emergency.


Clinical Trial Description

Oral Maxalt has an extensive record of providing relief of acute migraine headache with 2 hours in the vast majority of patients, especially when undertaken as an early intervention strategy. Caffeine has been demonstrated to have analgesic effects in patients treating tension type headache and is found as part of a combination including aspirin and acetaminophen as a treatment for acute migraine headache.

The mechanism by which Maxalt relieves migraine headache is believed to be through action on 5HT1B/1D receptors both on blood vessels as well as centrally. Caffeine may have effects on relief of migraine through modifying norepinephrine related mechanisms which have been suggested through clinical research. Patients commonly report that they may obtain partial or complete relief of their migraines by consuming the modest amounts of caffeine found in a cup of coffee. this is estimated to be approximately 100mg per cup. The analgesic effects of caffeine appear to be most significant in the first 3 hours after ingestion. Recent work suggests that intervention in migraine when the pain is still mild and has not persisted for a prolonged duration may increase the likelihood of complete migraine response. Therefore, the combination of the two agents with activity in migraine that work early in the migraine process, have good tolerability at the proposed doses and working via different mechanism may increase the likelihood of patients achieving better response with their migraine treatment than that which is currently available. ;


Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment


Related Conditions & MeSH terms


NCT number NCT00471952
Study type Interventional
Source Diamond Headache Clinic
Contact
Status Completed
Phase Phase 3
Start date April 2007
Completion date April 2008

See also
  Status Clinical Trial Phase
Recruiting NCT02202486 - Investigation of the Blood-brain and Blood-dura Barrier Durin Migraine Attacks Using MRI N/A
Completed NCT01687660 - Acupuncture for Migraine Prophylaxis N/A
Completed NCT00363532 - Functional MRI (fMRI) in CGRP Induced Migraine N/A
Completed NCT00123201 - Study to Evaluate the Efficacy and Safety of Dronabinol Metered Dose Inhaler (MDI) in Acute Treatment of Migraine Headache Phase 2
Completed NCT04406649 - A Study to Evaluate the Safety of STS101 in the Acute Treatment of Migraine Phase 3
Completed NCT03874832 - A Phase I Study to Study the PK and Safety of Single Doses of STS101, DHE Injection and Nasal Spray in Healthy Subjects Phase 1
Recruiting NCT05565001 - The Involvement of ATP Sensitive Potassium Channel in Migraine Aura and Migraine Pain. N/A
Completed NCT04533568 - Ibuprofen in Migraine Patients Phase 4
Recruiting NCT06459635 - Migraine Attack Pain Phase Prediction Study
Recruiting NCT05416476 - Anisodine Hydrobromide For The Preventive Treatment Of Episodic Migraine Phase 3
Completed NCT04636359 - Study the Effect of Acupuncture on Migraine Patient Without Aura Via Functional Magnetic Resonance Imaging. N/A
Completed NCT00534560 - Dose Ranging Study of the Efficacy and Tolerability of Tonabersat in the Prophylaxis of Migraine Headache Phase 2
Terminated NCT04936061 - Transnasal Cooling for Migraine N/A
Recruiting NCT05281770 - Monoclonal CGRP Antibodies for Migraine Prevention - a Nationwide Real Life Study
Completed NCT00380263 - PACAP38´s (Pituitary Adenylate Cyclase-Activating Polypeptide) Headache Inducing Characteristics and Effects on the Cerebral Blood Flow N/A
Completed NCT00334178 - Evaluation of the Efficacy and Safety of Laxymig® as Prophylactic Treatment in Patients With Migraine Phase 3
Recruiting NCT06051604 - Mi-Helper Transnasal Cooling for Acute Treatment of Migraine N/A
Recruiting NCT06414044 - Italian Real-life obServational Study on the effecTiveness, sAfety and Tolerability of Atogepant in Migraine Patients
Completed NCT03472378 - Can DFN-15 Terminate Migraine With Allodynia? Phase 2
Recruiting NCT05211154 - Evaluation of the Efficacy of Diclofenac Potassium and Rimegepant for the Acute Treatment of Migraine Phase 4